KRSA
NASDAQKorsana Biosciences Inc.
Korsana Biosciences Inc. (KRSA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for KRSA, including 3 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 13, 2026.
KRSA rankings
Price$31.50+0.49 (+1.58%)
2026-08-132026-11-13
Financial highlights
Full financials- Revenue, TTM
- $1.90M
- Revenue growth
- -12.6%
- Net income, TTM
- -$34.17M
- Net margin
- -1798.6%
- Cash
- $456.22M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks7+100%
2026-05-172026-11-08
Mix790d
- SEC Filings3(43%)
- Other1(14%)
- Earnings1(14%)
- 13D/G1(14%)
- Analyst1(14%)
Activity · 52 weeks75 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
7 items- ANALYSTWells Fargo initiated coverage on Korsana Biosciences with a new price targetWells Fargo initiated coverage of Korsana Biosciences with a rating of Overweight and set a new price target of $44.00
- 13D/GSEC Form SCHEDULE 13G filed by Korsana Biosciences Inc.SCHEDULE 13G - Korsana Biosciences, Inc. (0001755237) (Subject)
- SECSEC Form S-8 filed by Korsana Biosciences Inc.S-8 - Korsana Biosciences, Inc. (0001755237) (Filer)
- SECSEC Form 10-Q filed by Korsana Biosciences Inc.10-Q - Korsana Biosciences, Inc. (0001755237) (Filer)
- SECKorsana Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Korsana Biosciences, Inc. (0001755237) (Filer)
- PRKorsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateCompleted merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. ("Korsana" or the "Company") (NASDAQ:KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today reported financial results for the third quarter ended
- PRKorsana Biosciences to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. ("Korsana" or the "Company") (NASDAQ:KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences. Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 9, 2026, at 10:00 a.m. ET in Boston, MA.Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 1:20 p.m. ET in New York, NY.UBS Global Biopharma Conference 2026: Fireside chat on Monday, November 16, 2026, at 3:20 p.m. GMT in London, UK.Jeffer
KRSA FAQ
10 questionsWhat does Korsana Biosciences Inc. do?
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company's lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition...What is the latest news on KRSA?
In the last 30 days Quantisnow tracked 7 wire items for KRSA: 3 SEC filings, 1 press release or news item, 1 earnings update and 1 13D/G filing. The most recent was published on November 13, 2026.What is KRSA revenue?
Korsana Biosciences Inc. (KRSA) reported $1.90M of revenue for the twelve months ended Jun 30, 2026. That is down 12.6% from the year before. Revenue for fiscal 2025 was $2.07M.Is KRSA profitable?
No. Korsana Biosciences Inc. reported a net loss of $34.17M for the twelve months ended Jun 30, 2026.How much cash and debt does KRSA have?
Korsana Biosciences Inc. reported $456.22M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does KRSA stock trade?
Korsana Biosciences Inc. (KRSA) is listed on NASDAQ.What sector and industry is KRSA in?
Korsana Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KRSA?
Korsana Biosciences Inc. has had 1 recent analyst action on file. The most recent action was from Wells Fargo: Overweight with a $44.00 price target on 2026-11-13. Recent price targets cluster around $44.00.What companies are similar to KRSA?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare KRSA side-by-side with any of them on Quantisnow.How can I track KRSA on Quantisnow?
Quantisnow aggregates Korsana Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRSA to receive live email and push alerts on every new disclosure.